identified and validated that the EGLN1 gene might be a novel therapeutic target, preferentially associated with KRAS-mutated LUAD by integrating functional genomic analysis, in vitro data of cancer cell lines, gene druggability data, and patients’ transcriptomic and mutational data (37). Here, KRAS is linked to cancer.